Noemie Ranisavljevic

Dr. Noemie Ranisavljevic

Reproductive Medicine Unit, Univ Montpellier, CHU Montpellier, 34295 Montpellier, France
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2020 in Nature
Verified
Journal Article
Closed access
PDF file
SCSamuel Collombet
Samuel Collombet
NRNoemie Ranisavljevic
Noemie Ranisavljevic
TNTakashi Nagano
Takashi Nagano
CVCsilla Varnai
Csilla Varnai
TSTarak Shisode
Tarak Shisode
EHEdith Heard
Edith Heard

10 June 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
NRNoemie Ranisavljevic
Noemie Ranisavljevic
SHStephanie Huberlant
Stephanie Huberlant
MMMarie Montagut
Marie Montagut
PAPierre-Marie Alonzo
Pierre-Marie Alonzo
BDBernadette Darné
Bernadette Darné
ICIsabelle Cédrin-Durnerin
Isabelle Cédrin-Durnerin
Progesterone plays a key role in implantation. Several studies reported that lower luteal progesterone levels might be related to decreased chances of pregnancy. This systematic review was conducted using appropriate key words, on MEDLINE, EMBASE, and the Cochrane Library, from 1990 up to March 2021 to assess if luteal serum progesterone levels are associated with ongoing pregnancy (OP) and live birth (LB) rates (primary outcomes) and miscarriage rate (secondary outcome), according to the number of corpora lutea (CLs). Overall 2,632 non-duplicate records were identified, of which 32 relevant studies were available for quantitative analysis. In artificial cycles with no CL, OP and LB rates were significantly decreased when the luteal progesterone level falls below a certain threshold (risk ratio [RR] 0.72; 95% confidence interval [CI] 0.62–0.84 and 0.73; 95% CI 0.59–0.90, respectively), while the miscarriage rate was increased (RR 1.48; 95% CI 1.17–1.86). In stimulated cycles with several CLs, the mean luteal progesterone level in the no OP and no LB groups was significantly lower than in the OP and LB groups [difference in means 68.8 (95% CI 45.6–92.0) and 272.4 (95% CI 10.8–533.9), ng/ml, respectively]. Monitoring luteal serum progesterone levels could help in individualizing progesterone administration to enhance OP and LB rates, especially in cycles without corpus luteum.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=139019, identifier 139019.

28 June 2023 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
SBSophie Brouillet
Sophie Brouillet
NRNoemie Ranisavljevic
Noemie Ranisavljevic
CSCharlotte Sonigo
Charlotte Sonigo
EHE Haquet
E Haquet
SBS Bringer-Deutsch
S Bringer-Deutsch
TAT Anahory
T Anahory
Should we perform oocyte accumulation to preserve fertility in women with Turner syndrome (TS)? The oocyte cryopreservation strategy is not well adapted for all TS women as their combination of high basal FSH with low basal AMH and low percentage of 46,XX cells in the karyotype significantly reduces the chances of freezing sufficient mature oocytes for fertility preservation. An oocyte cryopreservation strategy requiring numerous stimulation cycles is needed to preserve fertility in TS women, to compensate for the low ovarian response, the possible oocyte genetic alterations, the reduced endometrial receptivity, and the increased rate of miscarriage, observed in this specific population. The validation of reliable predictive biomarkers of ovarian response to hormonal stimulation in TS patients is necessary to help practitioners and patients choose the best-personalized fertility preservation strategy. A retrospective bicentric study was performed from 1 January 2011 to 1 January 2023. Clinical and biological data from all TS women who have received from ovarian stimulation for fertility preservation were collected. A systematic review of the current literature on oocyte retrieval outcomes after ovarian stimulation in TS women was also performed (PROSPERO registration number: CRD42022362352). A total of 14 TS women who had undergone ovarian stimulation for fertility preservation were included, representing the largest cohort of TS patients published to date (n = 14 patients, 24 cycles). The systematic review of the literature identified 34 additional TS patients with 47 oocyte retrieval outcomes after ovarian stimulation in 14 publications (n = 48 patients, n = 71 cycles in total). The number of cryopreserved mature oocytes on the first cycle for TS patients was low (4.0 ± 3.7). Oocyte accumulation was systematically proposed to increase fertility potential and was accepted by 50% (7/14) of patients (2.4 ± 0.5 cycles), leading to an improved total number of 10.9 ± 7.2 cryopreserved mature oocytes per patient. In the group who refused the oocyte accumulation strategy, only one patient exceeded the threshold of 10 mature cryopreserved oocytes. In contrast, 57.1% (4/7) and 42.9% (3/7) of patients who have underwent the oocyte accumulation strategy reached the threshold of 10 and 15 mature cryopreserved oocytes, respectively (OR = 8 (0.6; 107.0), P = 0.12; OR= 11 (0.5; 282.1), P = 0.13). By analyzing all the data published to date and combining it with our data (n = 48 patients, n = 71 cycles), low basal FSH and high AMH concentrations as well as a higher percentage of 46,XX cells in the karyotype were significantly associated with a higher number of cryopreserved oocytes after the first cycle. Moreover, the combination of low basal FSH concentration (1.13 ng/ml), and the presence of 46,XX cells (>1%) was significantly predictive of obtaining at least six cryopreserved oocytes in the first cycle, representing objective criteria for identifying patients with real chances of preserving an adequate fertility potential by oocyte cryopreservation. Our results should be analyzed with caution, as the optimal oocyte number needed for successful live birth in TS patients is still unknown due to the low number of reports their oocyte use in the literature to date. TS patients should benefit from relevant clinical evaluation, genetic counseling and psychological support to make an informed choice regarding their fertility preservation technique, as numerous stimulation cycles would be necessary to preserve a high number of oocytes. This research received no external funding. The authors declare no conflict of interest. N/A.

Verified
Journal Article
Open access
PDF file
CBcecile BRUNET
cecile BRUNET
SASAFA AOUINTI
SAFA AOUINTI
FHFanchon Huguet
Fanchon Huguet
VMValerie macioce
Valerie macioce
NRNoemie Ranisavljevic
Noemie Ranisavljevic
ariane sultanariane sultan
ariane sultan
Access to in vitro fertilization (IVF) for obese women varies across centers, and the impact of obesity on IVF outcomes is widely discussed. We assessed the impact of obesity and its severity on live birth rate (LBR) after IVF. We included women treated for IVF in our center. Data were prospectively collected in the BabySentryTM software. LBR per cycle and cumulative LBR including all attempts of the couple were calculated, considering transfer of both fresh and frozen embryos. Of 1588 included women (2379 controlled ovarian stimulations), 70.2%, 19.5%, 7.9%, and 2.4% were normal-weight, overweight, class I obesity, and class II/III obesity, respectively. For each cycle, LBR did not differ according to BMI category. Adjusted odds ratios (95% confidence intervals) for obtaining a live birth at the first cycle were 1.11 (0.78–1.58) for overweight, 1.17 (0.70–1.95) for class I obese, and 1.05 (0.48–2.31) for class II/III obese women, as compared with normal-weight women. Similarly, no significant associations were found at cycles 2, 3, and 4. Cumulative LBR increased with the number of cycles, independently of the BMI class (p log-rank = 0.91). After adjustment, obesity status did not impact significantly the miscarriage rate, regardless of the cycle. In conclusion, neither women obesity nor its severity impacted the cumulative LBR after IVF.

2 June 2020 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
NRNoemie Ranisavljevic
Noemie Ranisavljevic
MHMathilde Hess
Mathilde Hess
CCChristel Castelli
Christel Castelli
MWMarjolene Willems
Marjolene Willems
AFAlice Ferrieres-Hoa
Alice Ferrieres-Hoa
TATal Anahory
Tal Anahory

20 October 2025 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
OCOrnella Cucchietti
Ornella Cucchietti
CMCaroline Mollevi
Caroline Mollevi
LMLionel Moulis
Lionel Moulis
TATal Anahory
Tal Anahory
SHStephanie Huberlant
Stephanie Huberlant
MDMartha Duraes
Martha Duraes